Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

ABSTRACT:

Background

Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Method

Participants in primary (n=18) and psychiatric (n=23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symp

SUBMITTER: Nierenberg AA 

PROVIDER: S-EPMC5886713 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature